Alphamab Oncology (HKG:9966)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
8.53
+0.23 (2.77%)
Jul 18, 2025, 11:44 AM HKT
277.43%
Market Cap7.99B
Revenue (ttm)681.16M
Net Income (ttm)177.02M
Shares Out962.19M
EPS (ttm)0.18
PE Ratio45.88
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,711,000
Average Volume3,774,035
Open8.50
Previous Close8.30
Day's Range8.37 - 8.75
52-Week Range2.10 - 9.35
Beta0.46
RSI67.21
Earnings DateAug 15, 2025

About Alphamab Oncology

Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the research, development, manufacture, and commercialization of oncology biologics. The company commercializes KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the ENQEIDA brand name. Its product pipeline includes KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) bispecific monoclonal antiboday that is i... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 420
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 9966
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.